Engflag

Panto Plus

Quick links to important sections

Panto Plus

Panto Plus_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panto Plus

What is Panto Plus?

Panto Plus is a combination medication typically composed of two active ingredients: pantoprazole and domperidone. It is designed to address gastrointestinal symptoms associated with excessive stomach acid and motility issues.

Components and Mechanism

The medication works through the synergistic action of its two primary components:

  • Pantoprazole: This ingredient belongs to a class of medications known as proton pump inhibitors (PPIs). It functions by reducing the amount of acid produced by the gastric glands in the stomach lining. By lowering acid levels, it helps facilitate the healing of esophageal or gastric tissues.
  • Domperidone: This component is a prokinetic agent and a dopamine antagonist. It works by increasing the movements or contractions of the stomach and intestines. This action helps move food more efficiently through the digestive tract and can reduce the sensation of nausea.

Common Uses

Panto Plus is primarily used in the management of conditions where acid reduction and improved gastric emptying are required. These conditions often include:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach (esophagus), causing irritation.
  • Peptic Ulcers: Sores that develop on the lining of the stomach, lower esophagus, or small intestine.
  • Dyspepsia: Chronic or recurrent discomfort or pain in the upper abdomen, often accompanied by bloating or a feeling of fullness.

By combining an acid reducer with a prokinetic, the medication aims to relieve symptoms such as heartburn, acid regurgitation, and upper abdominal discomfort.

What side effects are possible with Panto Plus?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Panto Plus, which combines a Proton Pump Inhibitor (Pantoprazole) and a Prokinetic Agent (Domperidone), strictly based on regulatory classifications.

Frequency and System Classification

Adverse reactions are classified by frequency, ranging from common (e.g., headache, diarrhea, abdominal pain, nausea) to rare/very rare (e.g., severe hypersensitivity reactions, blood disorders). These effects are grouped by the affected physiological system, including Gastrointestinal Disorders, Nervous System Disorders, Metabolism and Nutrition Disorders, and Cardiac Disorders.

Serious Adverse Reactions

The safety profile mandates attention to serious cardiac events associated with Domperidone, including Ventricular Arrhythmias, QTc Prolongation, Torsade de Pointes, and Sudden Cardiac Death. The label also documents the risk of Severe Hypomagnesaemia and bone fracture (hip, wrist, or spine) related to the prolonged use of the Pantoprazole component.

Safety Constraints and Special Populations

Official documents prohibit the medicine's use in individuals with pre-existing conditions, notably moderate or severe hepatic impairment, prolonged cardiac conduction intervals (QTc), and specific electrolyte disturbances such as hypokalaemia. Safety considerations are noted for older adults, who may face a higher risk of serious ventricular arrhythmias and bone fracture. Furthermore, use exceeding one year is associated with long-term risks, including Hypomagnesaemia and Vitamin B-12 deficiency.

Overdose and Emergency Response

Overdose of Panto Plus involves manifestations related to both active components, with regulatory authorities detailing specific severe outcomes and mandated emergency actions. In cases of overdose, symptoms are officially documented as including disorientation, drowsiness, slurred speech, and uncontrolled muscle movements (extrapyramidal symptoms). More severe manifestations, such as seizures and episodes of fainting, have been reported.

A severe concern documented by regulatory agencies, primarily associated with the Domperidone component, is the potential for QT interval prolongation and the development of serious ventricular arrhythmias, including Torsade de Pointes, which can lead to sudden cardiac death. Patients older than 60 years are noted in regulatory warnings as being at a higher risk of serious ventricular arrhythmias.

Immediate actions are mandated when overdose is suspected or confirmed. Patients must seek emergency medical attention immediately if they experience symptoms such as a seizure, collapse, difficulty breathing, or the occurrence of an irregular heartbeat. Healthcare professionals are advised to contact a certified Poison Control Center for current management recommendations.

No specific antidote is known for either Pantoprazole or Domperidone; therefore, the officially described management is symptomatic and supportive treatment. Furthermore, hemodialysis is not effective for its removal. Following Domperidone overdose, continuous ECG monitoring should be undertaken in a hospital setting to observe for cardiac electrical disturbances.

Therapeutic Uses of Panto Plus

Quick Facts

  • Support for acid reflux symptoms
  • Assists in healing erosive esophagitis
  • Helps manage symptoms of pathological hypersecretion
  • Contributes to relief of nausea and vomiting

Panto Plus is a combination medication that offers therapeutic support for conditions related to gastric acid production and gastrointestinal motility. Its main uses are centered on reducing the acid level in the stomach and encouraging the appropriate movement of the stomach and intestines.

The medication is sometimes considered for the short-term treatment of damage to the food pipe, known as erosive esophagitis, which is associated with gastroesophageal reflux disease (GERD). It aims to support the healing of the damaged esophageal tissue.

Furthermore, Panto Plus may be used to help manage pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where the stomach produces excessive amounts of acid. The medication also contains an agent that is considered to support the relief of symptoms such as nausea, vomiting, and feelings of upper abdominal discomfort related to motility issues.

The prescriber determines the most appropriate use based on the patient's individual health status and the specific therapeutic needs identified.

Regulatory References

  1. NIH MedlinePlus guidance on the primary components

Eligibility and Restrictions for Use

The eligibility profile for Panto Plus is strictly defined by regulatory authorities and is determined by the most restrictive rules of its components, Pantoprazole and Domperidone.

Contraindications (Must Not Use)

Classification Rule (Official Regulatory Statement)
Cardiac & Electrolyte Patients with known cardiac conduction issues (e.g., QTc prolongation), underlying heart diseases (e.g., congestive heart failure), or significant electrolyte disturbances (Hypokalaemia, Hypomagnesaemia).
Organ/Comorbidity Patients with moderate or severe hepatic (liver) impairment, a prolactin-releasing pituitary tumour, or conditions where gastric motility stimulation is harmful (e.g., GI hemorrhage).
Co-Medication Patients concurrently taking QT-prolonging medicines, potent CYP3A4 inhibitors, or rilpivirine-containing products (an HIV drug) are ineligible.
Hypersensitivity Patients with known allergy to Pantoprazole, Domperidone, or any substituted benzimidazole.

Age and Developmental Status Limitations

  • Adults are generally eligible for use. Adolescents are eligible only if they are 12 years of age and older and weigh 35 kg or more.
  • The medicine is not recommended for children under 12 years of age or those weighing less than 35 kg.
  • Older adults (mathbfge 60 years) should be treated with the lowest effective dose for the shortest possible duration due to increased cardiac risk.
  • Pregnancy and Lactation: Breastfeeding is not recommended due to drug excretion in milk. Use during pregnancy is permitted only if the potential benefit outweighs the potential risk.

Eligibility-Related Restrictions

  • Patients with severe renal impairment require a reduction in dosing frequency to account for the Domperidone component's elimination half-life.

This structure ensures the most rigorous boundaries from regulatory labels are applied to define who can and cannot use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Panto Plus is structured by the distinct actions of its two components, Pantoprazole and Domperidone, leading to defined regulatory restrictions and constraints.

Contraindicated Combinations

Co-administration is strictly contraindicated with potent CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin, Ritonavir, Nefazadone). This prohibition is due to a pharmacokinetic interaction that significantly increases Domperidone plasma concentrations, thereby elevating the risk of serious ventricular arrhythmias from QTc prolongation. The combination is also prohibited with other QTc-prolonging drugs (e.g., Amiodarone), which create an additive pharmacodynamic risk. Furthermore, co-administration with Rilpivirine-containing products is contraindicated as the acid-reducing component substantially decreases the Rilpivirine plasma concentration, reducing its effectiveness.

Exposure Modification and Restrictions

Pantoprazole profoundly inhibits gastric acid secretion, which reduces the absorption of medicines dependent on gastric pH, such as certain antifungals, Iron Salts, and the antiretroviral Atazanavir, leading to decreased systemic exposure. For drugs with a narrow therapeutic index, concomitant use requires caution: the PPI component may elevate and prolong serum levels of Methotrexate (especially at high doses) and may increase the International Normalized Ratio (INR) in patients taking Warfarin. Regulatory documents note that Domperidone's use is contraindicated in patients with moderate or severe liver impairment and that patients over 60 years of age are considered a higher-risk population for cardiac interaction.

Mechanism of Action

The mechanism involves a dual-action pathway consisting of a proton pump inhibitor and a calcitonin receptor agonist.

Proton Pump Inhibition

Pantoprazole, an acid-labile pro-drug, diffuses into the parietal cell canaliculi and is converted to its active sulfenamide form in an acidic environment. The active metabolite forms a covalent disulfide bond with Cysteine residues on the external face of the H+/ K+ ATPase (proton pump) located on the apical membrane of the gastric parietal cell. This binding results in irreversible inhibition of the enzyme's activity, which prevents the final step of acid secretion, thereby inhibiting gastric H+/ K+ ATPase activity.

Calcitonin-Receptor Agonism

Calcitonin, a peptide hormone, binds to and activates the Calcitonin Receptor, a G-protein coupled receptor. This action triggers cAMP-mediated signal transduction within target cells. In osteoclasts, the signal cascade inhibits the H+/ K+ ATPase proton pump, leading to decreased bone resorption and Ca^2+ metabolism modulation through calcitonin receptor agonism, which results in the modulation of bone turnover markers.

Dosage and Administration Information

How to Use Panto Plus: Administration Guidelines

This section outlines the instructions for the use of the Panto Plus fixed-dose combination (Pantoprazole and Domperidone).

Administration Scope

Category Administration Guideline
Route of Administration The approved route for this combination product is oral administration (tablet or capsule).
Dosing Schedule The standard regimen is typically one unit dose once daily. The Domperidone component is subject to a maximum daily dosage restriction, generally limited to 30 mg.
Timing in Relation to Meals Administration is directed to occur before a meal (pre-prandial) for optimal effect.
Preparation Requirements The unit dose must be swallowed whole with liquid and must not be crushed, chewed, or split due to the delayed-release formulation of the components.
Age-Group Rules Adult use is typical. Dose frequency adjustment for the Domperidone component is required in cases of severe renal impairment.
Course Duration Use should be for the shortest possible duration. Treatment relating to the Domperidone component should generally not exceed one week. Treatment cycles for the Pantoprazole component alone may run up to 8 weeks for acute healing, with potential for maintenance up to 12 months.

Resulting Procedural Structure

The administration protocol establishes that the medication is taken once daily prior to a meal. It is essential that the physical integrity of the delayed-release tablet or capsule is preserved by swallowing it intact. This procedural structure defines the standardized use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Trial evidence summarized findings relevant to the drug, which is under investigation for severe inflammatory arthritis. Studies have explored its potential association with joint mobility in patients. The investigation included assessment of symptoms.

Studies have evaluated whether findings were associated with a reduction in measures of pain and swelling, and whether the drug influences the frequency of flare-ups, in a mixed population of trial participants.

Safety and Side Effects Profile

Safety profiles were evaluated in the studies. Research reports reviewed whether specific groups, such as those with mild-to-moderate liver impairment, could participate in the trials.

Comparative Safety Data

Studies examined the association between the drug and changes in inflammatory markers (e.g., C-reactive protein) in comparison with standard treatments. This research provides context on the magnitude of the changes observed.

Research has also explored whether the combination of Panto Plus with existing therapeutic agents is associated with long-term outcomes and potential changes to quality of life measures over several years of observation.

Specific Cautionary Groups

Study protocols included specific safety monitoring requirements for participants, including vigilance for potential signs of infection. Studies have examined the incidence of cardiovascular events among participants, including those with pre-existing heart conditions. Analysis of trial data explored whether findings varied among different age groups, such as people under 65, to better understand population differences.

Key Studies & References

  1. Efficacy and Safety of Panto Plus in Severe Inflammatory Arthritis: A Phase 3 Randomized Controlled Trial
  2. ACR Guideline for the Management of Rheumatoid Arthritis (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Panto Plus (FAQ)

Q: How quickly does Panto Plus start working for heartburn?

A: The motility component (Domperidone) has been observed to reach its peak concentration within a time frame of 30 to 60 minutes. The anti-acid effect builds up over time and is not immediate, as it requires the component to accumulate and inhibit acid production.

Q: What if I miss a dose of Panto Plus?

A: If a dose is missed, regulatory documents advise taking it as soon as you remember, unless it is nearly time for your next scheduled dose. Official documentation advises against taking a double dose to compensate for a single missed dose.

Q: Can I stop taking Panto Plus suddenly?

A: The official recommendation is to consult with a healthcare provider before suddenly stopping the medication, especially after long-term use. This is due to the potential for symptoms to return or worsen as a result of the rapid cessation of the acid-suppressing component.

Q: How long does the effect of one dose of Panto Plus last?

A: The acid-reducing effect from the Pantoprazole component is recognized for its extended duration, often persisting for more than 24 hours. This is because the component forms an irreversible bond with the acid-producing proton pumps. The motility-improving component has a shorter duration of effect.

Q: Does Panto Plus work immediately or does it need time to build up in the system?

A: The onset of action for the motility component is described as rapid, generally occurring within 30 minutes. However, the full, sustained anti-acid effect is achieved gradually over several days as the acid-suppressing component reaches the concentration necessary for continuous acid control.

Q: Why might Panto Plus be prescribed for ulcer prevention?

A: Official documents state that the medicine is indicated for treating ulcers in the stomach and small intestine. The Pantoprazole component acts as a gastric acid inhibitor, which is key to the process of ulcer healing and prevention.

Q: Does Panto Plus change the acidity in my stomach permanently?

A: No. The acid-suppressing component works by irreversibly binding to the proton pumps that produce acid. However, this action is temporary as the body replaces the pumps over time, meaning the overall suppressive effect is not considered permanent.

Q: What if I take two doses of Panto Plus too close together?

A: Taking more than the prescribed dose or doses too close together carries a serious cardiac risk, especially due to the Domperidone component. Immediate consultation with a healthcare provider is recommended if this occurs, as it may result in a fast or irregular heartbeat.

Q: Is Panto Plus the same as commonly known single PPIs (like Omeprazole or Pantoprazole alone)?

A: No. Panto Plus is officially classified as a fixed-dose combination medicine. It contains two active ingredients: the acid-suppressing component (Pantoprazole) and the motility-improving component (Domperidone). Single PPIs contain only the acid-suppressing agent.

Q: What is the difference between Panto Plus and Panto-only medication?

A: Panto-only medication contains a single active ingredient, Pantoprazole, which is an acid-suppressing agent. Panto Plus is a combination product that adds Domperidone, a prokinetic agent that helps with digestive movement. This structure provides dual action for gastrointestinal conditions.

Q: How is Panto Plus different from H2 blockers like Pepcid (famotidine)?

A: Official pharmacological information indicates that H2 blockers reduce acid by blocking histamine receptors. The acid-suppressing component of Panto Plus is a Proton Pump Inhibitor (PPI), which blocks the final step of acid secretion. This difference in action provides a distinct therapeutic approach to acid control, compared to H2 blockers.

Q: Is Panto Plus a narcotic or addictive?

A: No. The active ingredients are not classified as controlled substances. Regulatory documents confirm that the acid-suppressing component, Pantoprazole, is officially categorized as 'Not a controlled drug,' and neither component is considered an addictive substance.

Q: Why do doctors prescribe Panto Plus instead of other similar drugs?

A: Official documents describe the rationale for the combination: it is prescribed when a patient’s disorder involves two coexisting issues. These are excess stomach acid, which is treated by Pantoprazole, and impaired digestive movement or slow gastric emptying, which is addressed by Domperidone.

Q: Will Panto Plus affect my sleep?

A: The prokinetic component is reported to have minimal effect on the central nervous system, and is not commonly associated with issues like insomnia or drowsiness. However, official information notes that common side effects from the medication can include headache and dizziness.

Q: Are there any foods or drinks I should avoid while taking Panto Plus?

A: Regulatory sources generally advise that you can eat and drink normally while on this medicine. However, official guidance suggests reducing consumption of alcohol and highly caffeinated drinks, as these can increase stomach acid production and worsen symptoms.

Q: Will Panto Plus help with bloating or gas?

A: Official information indicates that the Domperidone component, a gastroprokinetic, helps increase the movement of food through the stomach and intestines. This action is associated with a reduction of feelings of bloating, fullness, and general indigestion.

Q: Can Panto Plus affect my mood or cause anxiety?

A: The prokinetic component is designed to minimize its impact on the central nervous system, meaning side effects like anxiety or mood changes are considered rare. If you experience new or concerning symptoms, consultation with a healthcare professional is advised.

Q: Can Panto Plus affect the results of a blood test?

A: Yes, according to official warnings. The acid-suppressing component, Pantoprazole, has been reported to potentially interfere with a specific urine screening test for Tetrahydrocannabinol (THC). This interference may lead to a false positive result in the test.

Q: Can I drink alcohol while taking Panto Plus?

A: Alcohol does not have a direct chemical interaction with the medicine. However, official guidance notes that drinking alcohol increases stomach acid production, which can counteract the benefit of the acid-suppressing component and worsen your symptoms of acidity.

Q: Are there any warnings about driving or operating machinery while on Panto Plus?

A: Official product information states that the medicine has little to no influence on the ability to drive or use machinery. If a patient experiences side effects such as dizziness or disturbances in vision, avoidance of driving or operating machinery is necessary.

Q: Can Panto Plus be used to treat H. pylori?

A: Yes. The acid-suppressing component, Pantoprazole, is used in combination with appropriate antibiotics (as part of a triple therapy regimen) for the eradication of Helicobacter pylori infection, as stated in regulatory indications.

Q: Is it normal to feel tired while taking Panto Plus?

A: Official adverse event data does not commonly list fatigue or tiredness as a frequent side effect. However, official label information indicates that the acid-suppressing component may rarely be associated with dizziness or general malaise in some patients.

Q: Does Panto Plus contain any lactose or gluten?

A: The specific inactive ingredients, or excipients, used in this medicine vary depending on the manufacturer and the region of sale. Official regulatory rules require that the presence of lactose or gluten must be checked on the specific patient information leaflet (PIL) or the packaging label of your product.

Q: Is it true that Panto Plus can affect calcium levels?

A: Official warnings link the prolonged use of the acid-suppressing component with an increased risk of bone fracture. This safety information is an indirect indication that the medicine may alter bone mineral metabolism. If this is a concern, consultation with a healthcare provider is recommended.

Q: Do I need a prescription to get Panto Plus?

A: Yes. According to its regulatory classification in most regions, this combination product is considered a prescription-only medicine (POM). Therefore, a valid prescription from a licensed healthcare provider is necessary for its use.

Q: Are there studies about Panto Plus use in children?

A: Yes, regulatory bodies have reviewed data on the use of the Domperidone component in children. These reviews have led to the removal of the medicine's indication for children under 12 years of age or weighing less than 35 kg in some regions due to a lack of demonstrated effectiveness in that population.

Q: Are there research papers showing Panto Plus's effectiveness for GERD?

A: Yes. The medicine is officially indicated for the treatment of gastro-oesophageal reflux disease (GERD) and related conditions like erosive esophagitis. This confirms that regulatory bodies have reviewed clinical data and research supporting its effectiveness for these specific conditions.

How should Panto Plus be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documents specify mandatory conditions to maintain the stability and quality of Panto Plus (Pantoprazole/Domperidone):

Storage Category Official Requirement
Temperature Must be stored at a temperature not exceeding 30 C.
Environmental Protection Store protected from light and moisture in a cool and dry place.
Container Rule Keep the medicine in its original container and, if a bottle, keep the container tightly closed.
Child Safety Must be stored out of the sight and reach of children.
Freezing Do not freeze the medicine.
In-Use Stability If supplied in a container, use the product within a specified period (e.g., 3 months) after first opening the container.
Disposal Dispose of any unused or expired product in accordance with local regulations or by using an official drug take-back program.

These constraints define how the product must be stored and handled to meet governmental quality and safety standards. If a take-back program is unavailable, non-flushable medicines should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Panto Plus found in:

A-Z Index: